

**Exhibit 1**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(Dollars in thousands)**

	As of December 31, 2011	As of June 30, 2012
	US\$ (Note 1)	US\$ (unaudited)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	124,311	247,985
Short-term investments	479,173	462,088
Accounts receivable, net	200,437	194,346
Inventories	94,690	113,850
Value added tax receivables	10,833	20,457
Other receivables	16,590	13,356
Prepayments and deposits	9,792	11,111
Deferred tax assets, net	3,483	4,624
Total current assets	939,309	1,067,817
Other assets	7,330	9,238
Advances for purchase of plant and equipment	6,239	3,593
Property, plant and equipment, net	237,952	243,578
Land use rights, net	55,272	54,351
Intangible assets, net	84,029	84,768
Goodwill	128,840	133,063
Total assets	1,458,971	1,596,408
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Short-term bank loans	50,475	52,472
Notes payable	7,013	4,835
Accounts payable	48,501	68,368
Advances from customers	20,700	18,293
Salaries payable	38,784	37,207
Other payables	67,499	79,218
Income taxes payable	16,847	17,486
Other taxes payable	7,412	4,849
Total current liabilities	257,231	282,728
Long-term bank loans	35,025	85,063
Other long-term payables	2,355	3,401
Deferred tax liabilities, net	12,925	14,388
	50,305	102,852
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	486,314	504,856
Retained earnings	566,184	608,377
Accumulated other comprehensive income	100,139	92,786
Treasury stock	(10,160)	(6,345)
Total shareholders' equity	1,142,492	1,199,689
Non-controlling interests	8,943	11,139
Total equity	1,151,435	1,210,828
Total liabilities and shareholders' equity	1,458,971	1,596,408

(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F.

**Exhibit 2**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Dollars in thousands, except for share and per share data)

	Three months ended June 30,		Six months ended June 30,	
	2011	2012	2011	2012
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
Net revenues				
-PRC	90,729	115,294	163,182	207,134
- International	126,553	152,536	235,004	279,713
Net revenues	217,282	267,830	398,186	486,847
Cost of revenues	(93,486)	(114,208)	(174,671)	(212,900)
Gross profit	123,796	153,622	223,515	273,947
Selling expenses	(40,416)	(47,759)	(74,088)	(87,488)
General and administrative expenses	(17,437)	(26,111)	(31,864)	(45,725)
Research and development expenses	(18,504)	(23,877)	(37,092)	(48,154)
Operating income	47,439	55,875	80,471	92,580
Other income, net	1,752	388	2,178	973
Interest income	3,977	7,260	7,486	15,698
Interest expense	(381)	(1,287)	(601)	(1,978)
Income before income taxes and non-controlling interests	52,787	62,236	89,534	107,273
Provision for income taxes	(7,931)	(10,023)	(6,968)	(18,366)
Net income	44,856	52,213	82,566	88,907
Less: Net income attributable to non-controlling interests	(47)	(206)	(47)	(313)
Net income attributable to the Company	44,809	52,007	82,519	88,594
Basic earnings per share	0.38	0.45	0.72	0.76
Diluted earnings per share	0.37	0.44	0.70	0.74
Shares used in the computation of:				
Basic earnings per share	116,504,103	116,547,129	115,026,629	116,283,063
Diluted earnings per share	119,653,716	119,394,768	118,275,625	119,353,032

**Exhibit 3**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(Dollars in thousands)**

	Three months ended June 30,		Six months ended June 30,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
<b>Cash flow from operating activities:</b>				
Net income	44,809	52,007	82,519	88,594
Adjustments to reconcile net income to net cash from operating activities	9,621	22,078	21,935	36,593
Changes in current assets and liabilities	(20,647)	(12,731)	(38,373)	(3,711)
<b>Net cash generated from operating activities</b>	<b>33,783</b>	<b>61,354</b>	<b>66,081</b>	<b>121,476</b>
<b>Cash flow from investing activities:</b>				
Acquisition cost, net of cash acquired	(3,646)	—	(3,646)	(2,739)
Capital expenditures	(17,039)	(16,745)	(44,355)	(32,835)
Proceeds from sale of short-term investments	4,441	—	90,133	144,395
Increase in short-term investments and changes in others investing activities	(40,915)	(32,637)	(152,264)	(125,489)
<b>Net cash used in investing activities</b>	<b>(57,159)</b>	<b>(49,382)</b>	<b>(110,132)</b>	<b>(16,668)</b>
<b>Cash flow from financing activities:</b>				
Proceeds from bank loans	34,930	2,000	34,930	52,000
Dividends paid	(34,522)	—	(34,522)	(46,401)
Proceeds from exercise of options	3,112	4,691	4,347	14,138
Cash contribution from non-controlling interests	—	—	—	506
<b>Net cash generated from financing activities</b>	<b>3,520</b>	<b>6,691</b>	<b>4,755</b>	<b>20,243</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(19,856)</b>	<b>18,663</b>	<b>(39,296)</b>	<b>125,051</b>
Cash and cash equivalents at beginning of period	118,746	231,010	137,502	124,311
Effect of exchange rate changes on cash	724	(1,688)	1,408	(1,377)
<b>Cash and cash equivalents at end of period</b>	<b>99,614</b>	<b>247,985</b>	<b>99,614</b>	<b>247,985</b>

**Exhibit 4**
**MINDRAY MEDICAL INTERNATIONAL LIMITED**
**RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES**

(Dollars in thousands, except for share and per share data)

	Three months ended June 30,		Six months ended June 30,	
	2011	2012	2011	2012
	(unaudited) US\$	(unaudited) US\$	(unaudited) US\$	(unaudited) US\$
<b>Non-GAAP net income</b>	49,840	59,510	92,062	99,894
<i>Non-GAAP net margin</i>	22.9%	22.2%	23.1%	20.5%
Amortization of acquired intangible assets	(1,783)	(1,629)	(3,550)	(3,264)
Deferred tax impact related to acquired intangible assets	34	83	68	118
Share-based compensation	(3,282)	(5,957)	(6,061)	(8,154)
GAAP net income	44,809	52,007	82,519	88,594
<i>GAAP net margin</i>	20.6%	19.4%	20.7%	18.2%
Non-GAAP basic earnings per share	0.43	0.51	0.80	0.86
Non-GAAP diluted earnings per share	0.42	0.50	0.78	0.84
GAAP basic earnings per share	0.38	0.45	0.72	0.76
GAAP diluted earnings per share	0.37	0.44	0.70	0.74
Shares used in computation of:				
Basic earnings per share	116,504,103	116,547,129	115,026,629	116,283,063
Diluted earnings per share	119,653,716	119,394,768	118,275,625	119,353,032
<b>Non-GAAP operating income</b>	52,504	63,461	90,082	103,998
<i>Non-GAAP operating margin</i>	24.2%	23.7%	22.6%	21.4%
Amortization of acquired intangible assets	(1,783)	(1,629)	(3,550)	(3,264)
Share-based compensation	(3,282)	(5,957)	(6,061)	(8,154)
GAAP operating income	47,439	55,875	80,471	92,580
<i>GAAP operating margin</i>	21.8%	20.9%	20.2%	19.0%
<b>Non-GAAP gross profit</b>	125,152	154,796	226,193	276,245
<i>Non-GAAP gross margin</i>	57.6%	57.8%	56.8%	56.7%
Amortization of acquired intangible assets	(1,153)	(960)	(2,297)	(1,926)
Share-based compensation	(203)	(214)	(381)	(372)
GAAP gross profit	123,796	153,622	223,515	273,947
<i>GAAP gross margin</i>	57.0%	57.4%	56.1%	56.3%
<b>Non-GAAP selling expenses</b>	(38,483)	(45,472)	(70,449)	(83,838)
<i>Non-GAAP as % of total revenues</i>	17.7%	17.0%	17.7%	17.2%
Amortization of acquired intangible assets	(630)	(669)	(1,253)	(1,338)
Share-based compensation	(1,303)	(1,618)	(2,386)	(2,312)
GAAP selling expenses	(40,416)	(47,759)	(74,088)	(87,488)
<i>GAAP as % of total revenues</i>	18.6%	17.8%	18.6%	18.0%
<b>Non-GAAP general and administrative expenses</b>	(16,742)	(23,317)	(30,670)	(42,418)
<i>Non-GAAP as % of total revenues</i>	7.7%	8.7%	7.7%	8.7%
Share-based compensation	(695)	(2,794)	(1,194)	(3,307)
GAAP general and administrative expenses	(17,437)	(26,111)	(31,864)	(45,725)
<i>GAAP as % of total revenues</i>	8.0%	9.7%	8.0%	9.4%
<b>Non-GAAP research and development expenses</b>	(17,423)	(22,546)	(34,992)	(45,991)
<i>Non-GAAP as % of total revenues</i>	8.0%	8.4%	8.8%	9.4%
Share-based compensation	(1,081)	(1,331)	(2,100)	(2,163)
GAAP research and development expenses	(18,504)	(23,877)	(37,092)	(48,154)
<i>GAAP as % of total revenues</i>	8.5%	8.9%	9.3%	9.9%

**Exhibit 5****MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(Dollars in thousands)**

	Three months ended June 30,		Six months ended June 30,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
GAAP net income	44,809	52,007	82,519	88,594
Interest income	(3,977)	(7,260)	(7,486)	(15,698)
Interest expense	381	1,287	601	1,978
Provision for income tax	7,931	10,023	6,968	18,366
Earnings before interest and taxes ("EBIT")	49,144	56,057	82,602	93,240
Depreciation	5,213	7,451	10,261	14,041
Amortization	2,546	2,903	4,869	5,792
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	<u>56,903</u>	<u>66,411</u>	<u>97,732</u>	<u>113,073</u>